The Committee for Medicinal Products for Human Use (CHMP) has recommended that the immunotherapy be approved to treat adults ...
Strength in the pharmaceutical major’s oncology business offset weak China sales, but the company has warned of a potential ...
AstraZeneca ‘very disappointed’ after ditching £450m Liverpool vaccine site - Pascal Soriot, chief executive of AstraZeneca, ...
The company said, “In relation to the illegal drug importation allegations, in January 2025, AstraZeneca (AZN) received a Notice of Transfer to ...
Sales in China fell 3 per cent during the quarter. AstraZeneca said this was mainly because the winter had been mild, causing a drop in sales of respiratory drugs used to treat viral infections. It ...
AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with ...
AstraZeneca PLC on Thursday ended a strong year with better-than-expected fourth quarter earnings and said its pipeline would support further growth in 2025. The Cambridge-based pharmaceuticals firm ...
Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback